

# Ken B Waites

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594966/publications.pdf>

Version: 2024-02-01

88  
papers

5,240  
citations

156536

32  
h-index

97045

71  
g-index

90  
all docs

90  
docs citations

90  
times ranked

4120  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized trial of azithromycin to eradicate <i>Ureaplasma</i> respiratory colonization in preterm infants: 2-year outcomes. <i>Pediatric Research</i> , 2022, 91, 178-187.	1.1	8
2	Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 434-443.	0.9	5
3	A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria. <i>Future Microbiology</i> , 2022, 17, 397-410.	1.0	1
4	B-assembler: a circular bacterial genome assembler. <i>BMC Genomics</i> , 2022, 23, 361.	1.2	3
5	Septic polyarthrititis with <i>Mycoplasma salivarium</i> in a patient with common variable immunodeficiency: case report and review of the literature. <i>Access Microbiology</i> , 2021, 3, 000221.	0.2	7
6	<i>Trichomonas vaginalis</i> Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0026421.	1.8	9
7	Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials. <i>Antibiotics</i> , 2021, 10, 1489.	1.5	3
8	Molecular Characterization of <i>Mycoplasma pneumoniae</i> Isolates in the United States from 2012 to 2018. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	32
9	Hyperammonemia syndrome due to <i>Ureaplasma urealyticum</i> in a kidney transplant recipient: A case of disseminated disease from a fluoroquinolone-resistant isolate. <i>Transplant Infectious Disease</i> , 2020, 22, e13328.	0.7	9
10	Macrolide-resistant <i>Mycoplasma pneumoniae</i> pneumonia in transplantation: Increasingly typical?. <i>Transplant Infectious Disease</i> , 2020, 22, e13318.	0.7	2
11	<i>In Vitro</i> Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
12	<i>Mycoplasma genitalium</i> Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	16
13	Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in <i>Mycoplasma pneumoniae</i> . <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	9
14	Randomised trial of azithromycin to eradicate <i>Ureaplasma</i> in preterm infants. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2020, 105, 615-622.	1.4	45
15	<i>Mycoplasma pneumoniae</i> Carriage With De Novo Macrolide-Resistance and Breakthrough Pneumonia. <i>Pediatrics</i> , 2019, 144, e20191642.	1.0	14
16	Evaluation of the ELITE InGenius PCR Platform for Detection of <i>Mycoplasma pneumoniae</i> . <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	8
17	<i>Mycoplasma genitalium</i> Infections With Macrolide and Fluoroquinolone Resistance-Associated Mutations in Heterosexual African American Couples in Alabama. <i>Sexually Transmitted Diseases</i> , 2019, 46, 18-24.	0.8	28
18	<i>Mycoplasma genitalium</i> Coinfection in Women With <i>Chlamydia trachomatis</i> Infection. <i>Sexually Transmitted Diseases</i> , 2019, 46, e101-e104.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Allergic airway sensitization impairs antibacterial IgG antibody responses during bacterial respiratory tract infections. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1183-1197.e7.	1.5	3
20	Two cases of multidrug-resistant genitourinary <i>Mycoplasma genitalium</i> infection successfully eradicated with minocycline. <i>International Journal of STD and AIDS</i> , 2019, 30, 512-514.	0.5	15
21	Azithromycin-based Extended-Spectrum Antibiotic Prophylaxis for Cesarean: Role of Placental Colonization with Genital <i>Ureaplasmas</i> and <i>Mycoplasmas</i> . <i>American Journal of Perinatology</i> , 2019, 36, 1002-1008.	0.6	6
22	Evaluation of a real-time PCR assay for detection of <i>Mycoplasma genitalium</i> and macrolide resistance-mediating mutations from clinical specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 123-125.	0.8	16
23	High Prevalence of Multidrug-Resistant <i>Mycoplasma genitalium</i> in Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Alabama. <i>Clinical Infectious Diseases</i> , 2018, 66, 796-798.	2.9	59
24	Analysis of the tonsillar microbiome in young adults with sore throat reveals a high relative abundance of <i>Fusobacterium necrophorum</i> with low diversity. <i>PLoS ONE</i> , 2018, 13, e0189423.	1.1	18
25	Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens. <i>MSphere</i> , 2017, 2, .	1.3	27
26	Beyond the uterine environment: a nonhuman primate model to investigate maternal-fetal and neonatal outcomes following chronic intrauterine infection. <i>Pediatric Research</i> , 2017, 82, 244-252.	1.1	20
27	<i>Mycoplasma pneumoniae</i> from the Respiratory Tract and Beyond. <i>Clinical Microbiology Reviews</i> , 2017, 30, 747-809.	5.7	411
28	<i>Ureaplasma</i> Transmitted From Donor Lungs Is Pathogenic After Lung Transplantation. <i>Annals of Thoracic Surgery</i> , 2017, 103, 670-671.	0.7	45
29	Shaken or stirred?: Comparison of methods for dispersion of <i>Mycoplasma pneumoniae</i> aggregates for persistence in vivo. <i>Journal of Microbiological Methods</i> , 2017, 132, 56-62.	0.7	9
30	In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant <i>Mycoplasma pneumoniae</i> from the United States, Europe, and China. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	53
31	New Horizons in <i>Mycoplasma genitalium</i> Treatment. <i>Journal of Infectious Diseases</i> , 2017, 216, S412-S419.	1.9	78
32	In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human <i>Mycoplasmas</i> and <i>Ureaplasmas</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	12
33	Inter- and intra-strain variability of tandem repeats in <i>Mycoplasma pneumoniae</i> based on next-generation sequencing data. <i>Future Microbiology</i> , 2017, 12, 119-129.	1.0	7
34	<i>Ureaplasma</i> infection-mediated release of matrix metalloproteinase-9 and PGP: a novel mechanism of preterm rupture of membranes and chorioamnionitis. <i>Pediatric Research</i> , 2017, 81, 75-79.	1.1	21
35	Intra-amniotic <i>Ureaplasma parvum</i> Induced Maternal and Fetal Inflammation and Immune Responses in Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2016, 214, 1597-1604.	1.9	32
36	In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human <i>Mycoplasmas</i> and <i>Ureaplasmas</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7502-7504.	1.4	33

#	ARTICLE	IF	CITATIONS
37	Contaminated open fracture and crush injury: a murine model. <i>Bone Research</i> , 2015, 3, 14050.	5.4	11
38	Macrolide-Resistant <i>Mycoplasma pneumoniae</i> , United States. <i>Emerging Infectious Diseases</i> , 2015, 21, 1470-1472.	2.0	84
39	Specificity and Strain-Typing Capabilities of Nanorod Array-Surface Enhanced Raman Spectroscopy for <i>Mycoplasma pneumoniae</i> Detection. <i>PLoS ONE</i> , 2015, 10, e0131831.	1.1	19
40	The Clinical Presentation of <i>Fusobacterium</i> -Positive and Streptococcal-Positive Pharyngitis in a University Health Clinic. <i>Annals of Internal Medicine</i> , 2015, 162, 241-247.	2.0	94
41	<i>In Vitro</i> Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3627-3629.	1.4	20
42	Comparison of Molecular Characteristics of <i>Mycoplasma pneumoniae</i> Specimens Collected from the United States and China. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3891-3893.	1.8	8
43	Comparative genome analysis of <i>Mycoplasma pneumoniae</i> . <i>BMC Genomics</i> , 2015, 16, 610.	1.2	59
44	Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 570-578.	1.4	31
45	Characterization of <i>Mycoplasma pneumoniae</i> Infection and Outcomes in the SOLITAIRE-Oral, Global Phase 3 Clinical Trial for Solithromycin. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.4	1
46	Suppression of Antimicrobial Peptide Expression by Ureaplasma Species. <i>Infection and Immunity</i> , 2014, 82, 1657-1665.	1.0	30
47	Comparison of the <i>illumina</i> gene <i>Mycoplasma</i> DNA Amplification Assay and Culture for Detection of <i>Mycoplasma pneumoniae</i> . <i>Journal of Clinical Microbiology</i> , 2014, 52, 1060-1063.	1.8	49
48	<i>Mycoplasma pneumoniae</i> Infections in Childhood. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 92-94.	1.1	93
49	Type 1 and type 2 strains of <i>Mycoplasma pneumoniae</i> form different biofilms. <i>Microbiology (United Kingdom)</i> 155, 1077-1084. doi:10.1099/mic/0/000000.0	0.7	59
50	Antimicrobial Susceptibilities and Treatment Options for Pediatric <i>Mycoplasma pneumoniae</i> Infections - Does Macrolide Resistance Matter?. <i>Current Pediatric Reviews</i> , 2013, 9, 279-288.	0.4	3
51	Standardized Methods and Quality Control Limits for Agar and Broth Microdilution Susceptibility Testing of <i>Mycoplasma pneumoniae</i> , <i>Mycoplasma hominis</i> , and <i>Ureaplasma urealyticum</i> . <i>Journal of Clinical Microbiology</i> , 2012, 50, 3542-3547.	1.8	71
52	Molecular Methods for the Detection of <i>Mycoplasma</i> and <i>Ureaplasma</i> Infections in Humans. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 437-450.	1.2	124
53	What's New in Diagnostic Testing and Treatment Approaches for <i>Mycoplasma pneumoniae</i> Infections in Children?. <i>Advances in Experimental Medicine and Biology</i> , 2012, 719, 47-57.	0.8	12
54	Antimicrobial activity of PVP from an Antarctic bacterium, <i>Janthinobacterium</i> sp. Ant5-2, on multi-drug and methicillin resistant <i>Staphylococcus aureus</i> . <i>Natural Products and Bioprospecting</i> , 2012, 2, 104-110.	2.0	17

#	ARTICLE	IF	CITATIONS
55	Stevens-Johnson Syndrome in a Boy With Macrolide-Resistant <i>Mycoplasma pneumoniae</i> Pneumonia. <i>Pediatrics</i> , 2011, 127, e1605-e1609.	1.0	17
56	Detection of <i>Mycoplasma pneumoniae</i> in Simulated and True Clinical Throat Swab Specimens by Nanorod Array-Surface-Enhanced Raman Spectroscopy. <i>PLoS ONE</i> , 2010, 5, e13633.	1.1	57
57	Critical Role of Macrophages and Their Activation via MyD88-NF $\kappa$ B Signaling in Lung Innate Immunity to <i>Mycoplasma pneumoniae</i> . <i>PLoS ONE</i> , 2010, 5, e14417.	1.1	63
58	Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2139-2141.	1.4	77
59	The role of <i>Mycoplasma</i> in upper respiratory infections. <i>Current Infectious Disease Reports</i> , 2009, 11, 198-206.	1.3	38
60	Congenital and opportunistic infections: <i>Ureaplasma</i> species and <i>Mycoplasma hominis</i> . <i>Seminars in Fetal and Neonatal Medicine</i> , 2009, 14, 190-199.	1.1	162
61	Emerging Macrolide Resistance in <i>Mycoplasma pneumoniae</i> in Children. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 693-696.	1.1	104
62	Epidemiology, clinical manifestations, pathogenesis and laboratory detection of <i>Mycoplasma pneumoniae</i> infections: Figure 1. <i>FEMS Microbiology Reviews</i> , 2008, 32, 956-973.	3.9	386
63	New insights into the pathogenesis and detection of <i>Mycoplasma pneumoniae</i> infections. <i>Future Microbiology</i> , 2008, 3, 635-648.	1.0	179
64	Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3776-3778.	1.4	12
65	Revaccination of Adults With Spinal Cord Injury Using the 23-Valent Pneumococcal Polysaccharide Vaccine. <i>Journal of Spinal Cord Medicine</i> , 2008, 31, 53-59.	0.7	11
66	Evaluation of 3 Methods of Bladder Irrigation to Treat Bacteriuria in Persons With Neurogenic Bladder. <i>Journal of Spinal Cord Medicine</i> , 2006, 29, 217-226.	0.7	58
67	Mycoplasmas and Ureaplasmas as Neonatal Pathogens. <i>Clinical Microbiology Reviews</i> , 2005, 18, 757-789.	5.7	504
68	In vitro comparison of agar and microbroth dilution methods for determination of MICs for <i>Mycoplasma hominis</i> . <i>Journal of Microbiological Methods</i> , 2005, 60, 285-288.	0.7	9
69	Effective Communication of Antimicrobial Susceptibility Data by Pathologists to Clinicians. , 2005, 563, 165-177.		1
70	<i>Mycoplasma pneumoniae</i> and Its Role as a Human Pathogen. <i>Clinical Microbiology Reviews</i> , 2004, 17, 697-728.	5.7	1,069
71	Effect Of Cranberry Extract On Bacteriuria and Pyuria in Persons With Neurogenic Bladder Secondary To Spinal Cord Injury. <i>Journal of Spinal Cord Medicine</i> , 2004, 27, 35-40.	0.7	70
72	Microbiology Of The Urethra and Perineum and Its Relationship To Bacteriuria In Community-Residing Men With Spinal Cord Injury. <i>Journal of Spinal Cord Medicine</i> , 2004, 27, 448-452.	0.7	16

#	ARTICLE	IF	CITATIONS
73	New concepts of <i>Mycoplasma pneumoniae</i> infections in children. <i>Pediatric Pulmonology</i> , 2003, 36, 267-278.	1.0	132
74	Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against <i>Mycoplasma pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2003, 21, 574-577.	1.1	24
75	Dissemination of Macrolide-Resistant <i>Streptococcus pneumoniae</i> Isolates Containing Both erm (B) and mef (A) in South Korea. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5787-5791.	1.8	22
76	In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 39-42.	1.4	57
77	Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3973-3975.	1.4	44
78	In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 161-165.	1.4	73
79	Antimicrobial Resistance among Isolates of Respiratory Tract Infection Pathogens from the Southern United States: Data from the PROTEKT US Surveillance Program 2000/2001. <i>Southern Medical Journal</i> , 2003, 96, 974-985.	0.3	18
80	Bacteremia after Spinal Cord Injury in Initial Versus Subsequent Hospitalizations. <i>Journal of Spinal Cord Medicine</i> , 2001, 24, 96-100.	0.7	39
81	The MB/BacT Is a Sensitive Method of Isolating <i>Mycobacterium tuberculosis</i> from Clinical Specimens in a Laboratory with a Low Rate of Isolation. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3133-3134.	1.8	0
82	Susceptibility of <i>Pseudomonas aeruginosa</i> to Levofloxacin and Trovafloxacin Based on MICs for Ciprofloxacin and Ofloxacin. <i>Drugs</i> , 1999, 58, 211-213.	4.9	0
83	Susceptibility of <i>Mycoplasma hominis</i> to Moxifloxacin by E-Test and Agar Dilution. <i>Drugs</i> , 1999, 58, 406-407.	4.9	3
84	Effect of Oral Ciprofloxacin on Bacterial Flora of Perineum, Urethra, and Lower Urinary Tract in Men with Spinal Cord Injury. <i>Journal of Spinal Cord Medicine</i> , 1999, 22, 192-198.	0.7	20
85	Development of a reverse transcription-polymerase chain reaction assay for diagnosis of lymphocytic choriomeningitis virus infection and its use in a prospective surveillance study. <i>Journal of Medical Virology</i> , 1997, 51, 107-114.	2.5	51
86	Compliance with Annual Urologic Evaluations and Preservation of Renal Function in Persons with Spinal Cord Injury. <i>Journal of Spinal Cord Medicine</i> , 1995, 18, 251-254.	0.7	17
87	Emerging from Obscurity: Understanding Pulmonary and Extrapulmonary Syndromes, Pathogenesis, and Epidemiology of Human <i>Mycoplasma pneumoniae</i> Infections. , 0, , 57-84.		24
88	<i>Mycoplasma</i> and <i>Ureaplasma</i> . , 0, , 1088-1105.		15